Adicet Bio CFO reports tax share withholding

Adicet Bio Chief Financial Officer Brian Nicholas Harvey reported a routine tax withholding related to restricted stock units.

Accepted by SEC EDGAR 01/27/2026 - 04:43 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Adicet Bio Chief Financial Officer Brian Nicholas Harvey reported a routine tax withholding related to restricted stock units. On January 24, 2026, 546 shares of Adicet Bio common stock were withheld at $8.44 per share to cover tax obligations upon RSU vesting, and this did not involve an open-market sale. After this withholding and giving effect to a 1-for-16 reverse stock split completed on December 30, 2025, he beneficially owned 5,145 common shares directly.

Insider Trade Summary

Exercise Price or Tax Liability: 546 shares

Exercise Price or Tax Liability 1 txn

Insider Harvey Brian Nicholas

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	546	$8.44	$5K

Holdings After Transaction: Common Stock — 5,145 shares (Direct)

Holdings Before and After: Common Stock, 5,691 to 5,145 shares (Direct)

Footnotes (2)

1. F1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.
2. F2. Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Adicet Bio (ACET) report for its CFO?

Adicet Bio reported a routine tax withholding transaction for its CFO, Brian Nicholas Harvey. On January 24, 2026, 546 common shares were withheld to satisfy tax obligations arising from vesting restricted stock units, rather than being sold on the open market.

How many Adicet Bio (ACET) shares were involved in the CFO’s Form 4 filing?

The Form 4 shows 546 Adicet Bio common shares were withheld. These shares were taken by the company to cover tax withholding obligations triggered when the CFO’s restricted stock units vested, according to the footnote explanation in the filing.

Did the Adicet Bio (ACET) CFO actually sell shares in this Form 4?

No, the filing states the transaction does not represent a sale by the CFO. The 546 shares of common stock were withheld by Adicet Bio solely to satisfy tax withholding obligations connected to vesting restricted stock units.

How many Adicet Bio (ACET) shares does the CFO own after this transaction?

Following the reported transaction, the CFO beneficially owns 5,145 Adicet Bio common shares directly. This amount already reflects the impact of the company’s previously effected 1-for-16 reverse stock split noted in the footnotes.

What does transaction code “F” mean in the Adicet Bio (ACET) Form 4?

Transaction code “F” indicates shares withheld to pay taxes on equity awards. In this case, Adicet Bio withheld 546 shares from the CFO to cover tax obligations tied to the vesting of restricted stock units, rather than recording a discretionary stock sale.

How is the 1-for-16 reverse stock split relevant to the Adicet Bio (ACET) Form 4?

A footnote explains that the reported holdings reflect a 1-for-16 reverse stock split effected on December 30, 2025. This means the 5,145 common shares shown as beneficially owned are already adjusted for that reverse split ratio.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Harvey Brian Nicholas

(Last) (First) (Middle)

C/O ADICET BIO, INC.

131 DARTMOUTH STREET, FLOOR 3

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Adicet Bio, Inc. [ ACET ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/24/2026		F(1)		546	D	$8.44	5,145(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the vesting of restricted stock units and does not represent a sale by the Reporting Person.

2. Reflects a 1-for-16 reverse stock split effected by the Issuer on December 30, 2025.

	/s/ Nick Harvey	01/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.